Relationship between patient profile and feverishness developed during interferon-ribavirin combination therapy of chronic hepatitis C patients

Yakugaku Zasshi

Volumn 128, Issue 12, 2008, Pages 1803-1810

  Motegi, Eriko ^a   Uesawa, Yoshihiro ^a   Dai, Yuko ^b   Ishii, Kiyoshi ^b   Mohri, Kiminori ^a  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^b Saitama Social Insurance Hospital   (Japan)

Author keywords

Chronic hepatitis C; Feverishness; Pegylated interferon; Sex difference

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; HEMOGLOBIN; NONSTEROID ANTIINFLAMMATORY AGENT; PEGINTERFERON; RIBAVIRIN;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BODY TEMPERATURE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FEVER; GENOTYPE; GERIATRIC CARE; HEALTH SURVEY; HEPATITIS C; HEPATITIS C VIRUS; HOSPITALIZATION; HUMAN; LABORATORY TEST; LEUKOCYTE; MALE; UREA NITROGEN BLOOD LEVEL;

ADULT; AGED; AGING; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FEVER; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX CHARACTERISTICS;

EID: 57149108729     PISSN: 00316903     EISSN: 13475231     Source Type: Journal    
DOI: 10.1248/yakushi.128.1803     Document Type: Article

References (16)

1. Bukowski R., Ernstoff M. S., Gore M. E., Nemunaitis J. J., Amato R., Gupta S. K., Tendler C. L., J. Clin. Oncol., 20, 3841-3849 (2002).
2. Osaka hepatitis/hepatoma task force, "Guideline on the Management of the Viral Hepatitides C" (2005).
3. National Institute of Diabetes and Digestive and Kidney Diseases, 〈http://digestive.niddk.nih.gov/ddiseases/pubs/chronichepc/〉, NIH.
4. Schering-Plough Corporation, Package Insert of PegIntron™ 2007 (2007).
5. Quesada J. R., Talpaz M., Rios A., Kurzrock R., Gutterman J. U., J Clin. Oncol., 4, 234-243 (1986).
6. Mizushima Y., Tei M., Yahune A., Higashio N., Inagami M., Iwado T., Uno K., Inflammation, 8, 475-482 (1988).
7. Naganuma H., Mochizuki Y., Kawahara Y., Rinshoiyaku, 9, 1219-1237 (1986).
8. Gupta S. K., Swan S. K., Marbury T., Smith W., Schwartz S., Kolz K., Cutler D., Br. J. Clin. Pharmacol., 64, 726-732 (2007).
9. Jain A. B., Eghtesad B., Venkataramanan R., Fontes P. A., Kashyap R., Dvorchik I., Shakil A. O., Kingery L., Fung J. J., Liver Transpl., 8, 1007-1013 (2002).
10. James G. D., Sealey J. E., Alderman M., Ljungman S., Mueller F. B., Pecker M. S., Laragh J. H., Am. J. Hypertens., 1, 124-131 (1988).
11. Lockshin M. D., Lupus, 15, 753-756 (2006).
12. Klein S. L., Parasite Immunol., 26, 247-264 (2004).
13. Lamason R., Zhao P., Rawat R., Davis A., Hall J. C., Chae J. J., Agarwal R., Cohen P., Rosen A., Hoffman E. P., Nagaraju K., BMC Immunol., 7, 1-14 (2006).
14. Cernetich A., Garver L. S., Jedlicka A. E., Klein P. W., Kumar N., Scott A. L., Klein S. L., Infect. Immun., 74, 3190-3203 (2006).
15. Berghöfer B., Frommer T., Haley G., Fink L., Bein G., Hackstein H., J. Immunol., 177, 2088-2096 (2006).
16. Dinarello C. A., Bernheim H. A., Duff G. W., Le H. V., Nagabhushan T. L., Hamilton N. C., Coceani F., J. Clin. Invest., 74, 906-913 (1984).